Basic information
Biomarker: CA19-9
Histology type: endometrial carcinoma
Cohort characteristics
Followed up time :
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 257 | endometrial carcinoma before treatment | 225 | recurrent endometrial carcinoma | 32 |
Sample information
Conclusion: In 34.4% of the 32 recurrent cases, elevated levels of the tumor markers were the first sign of recurrence. These data indicate that the use of CA19-9 in combination with CA125 is noteworthy in the management of patients with endometrial carcinoma.
Sample type : serum
Expression pattern : expression(CA19-9 and CA 125 )
Disease information
Related information
UniProt Link:
Molecular function from UniProt:
